ConMed
Valuation each multiple against its own 5-year range
Vs. peers Medical Devices
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| ConMed (CNMD) | 1.39B | 19.32 | 1.31 | 0.00% |
| Abbott Laboratories (ABT) | 178.39B | 38.29 | 3.50 | 2.41% |
| Medtronic (MDT) | 127.84B | 24.62 | 2.54 | 2.85% |
| Stryker Corp (SYK) | 118.01B | 33.01 | 5.03 | 1.14% |
| Boston Scientific (BSX) | 60.85B | 17.71 | 2.37 | 0.00% |
| Edwards Lifesciences (EW) | 58.56B | 57.54 | 5.39 | 0.00% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 33.5% below Morningstar's fair value estimate.
Fair value
Conmed Corp earns a 4-star quantitative star rating, illustrating our stance that this share class offers a somewhat attractive opportunity for investors. The stock currently trades at a 19% discount to our quantitative fair value estimate of $62.14 per share; however, some caution is warranted due to this estimate's medium uncertainty rating.
The firm's profitability strengthens our estimated fair value. Highly profitable companies are often more resilient in recessions and are likely to generate stronger future cash flows for shareholders. Reflecting the firm's profitability is its earnings yield of 9.2%, which sits in the top 30% globally. This suggests that it is generating substantial earnings relative to its share price, which contributes to our view that shares are cheap.
The company's valuation metrics are an additional encouraging factor. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's book value yield of 68.9%, a core component of valuation, sits in the top 45% compared with global peers. The market price is low relative to the book (accounting) value of the company's equity, which further promotes our favorable price/fair value ratio.
Economic moat
This company lacks a competitive advantage, receiving a quantitative economic moat rating of none. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.
By Quantitative Equity Report
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
ConMed discussion 0 comments